Bill > HB1270

This bill establishes a comprehensive framework for patients with life-threatening or severely debilitating illnesses to access individualized investigational medical treatments that are uniquely developed based on their personal genetic profile. The legislation allows eligible patients, in consultation with their treating physician, to request and receive investigational drugs, biological products, or devices (such as gene therapies, antisense oligonucleotides, and personalized neoantigen vaccines) that are specifically created for their unique medical condition after considering all currently approved treatment options. The bill provides robust protections for manufacturers, healthcare providers, and patients by ensuring that healthcare providers cannot have their licenses or Medicare certifications revoked for recommending these treatments, manufacturers are not required to provide the treatments and are protected from legal action if they act in good faith, and patients must provide comprehensive informed consent that clearly outlines potential risks and outcomes. Additionally, the bill specifies that health insurance providers are not obligated to cover these experimental treatments, and patients or their estates are responsible for associated costs. The legislation aims to give terminally ill patients more autonomy in exploring potential life-saving treatments while establishing clear guidelines and safeguards for all parties involved.

Health and Social Services

https://leg.colorado.gov/bills/hb25-1270